Regulatory Impurity Qualification

Regulatory Impurity Qualification is a formal scientific assessment process within the broader category of process-related impurities that establishes the safety and acceptable levels of impurities in pharmaceutical products through regulatory-approved methodologies, distinguishing it by its requirement for compliance with health authority guidelines and submission in regulatory dossiers.

2

Publications

126

Citations

40

Authors

23

Institutions

Publications per year

2017–2026

1

Authors

40

  1. JP
    Joel P. Bercu

    Gilead Sciences (United States), United States

    2 publications · 126 citations

    2

    h-index

  2. JN
    John Nicolette

    AbbVie (United States), United States

    2 publications · 126 citations

    2

    h-index

  3. SG
    Susanne Glowienke

    Novartis (Switzerland), Switzerland

    1 publications · 113 citations

    1

    h-index

  4. RA
    Robert A. Jolly

    Eli Lilly (United States), United States

    1 publications · 113 citations

    1

    h-index

  5. TC
    Teresa C. Wegesser

    University of California, Davis, United States

    1 publications · 13 citations

    1

    h-index

1–5 of 40

Venues

  1. Regulatory Toxicology and Pharmacology

    RTP · 2 publications · 126 citations

    2

    h-index

1–2